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Background: The immune surveillance reactivator lefitolimod (MGN1703), a DNA-based TLR9 agonist, might foster innate and
adaptive immune response and thus improve immune-mediated control of residual cancer disease. The IMPULSE phase II study
evaluated the efficacy and safety of lefitolimod as maintenance treatment in extensive-stage small-cell lung cancer (ES-SCLC)
after objective response to first-line chemotherapy, an indication with a high unmet medical need and stagnant treatment
improvement in the last decades.
Patients and methods: 103 patients with ES-SCLC and objective tumor response (as per RECIST 1.1) following four cycles of
platinum-based first-line induction therapy were randomized to receive either lefitolimod maintenance therapy or local
standard of care at a ratio of 3 : 2 until progression or unacceptable toxicity.
Results: From 103 patients enrolled, 62 were randomized to lefitolimod, 41 to the control arm. Patient demographics and
response patterns to first-line therapy were balanced. Lefitolimod exhibited a favorable safety profile and pharmacodynamic
assessment confirmed the mode-of-action showing a clear activation of monocytes and production of interferon-gamma-
induced protein 10 (IP-10). While in the intent-to-treat (ITT) population no relevant effect of lefitolimod on progression-free and
overall survival (OS) could be observed, two predefined patient subgroups indicated promising results, favoring lefitolimod with
respect to OS: in patients with a low frequency of activated CD86þ B cells (hazard ratio, HR 0.53, 95% CI: 0.26–1.08; n¼ 38 of 88
analyzed) and in patients with reported chronic obstructive pulmonary disease (COPD) (HR 0.48, 95% CI: 0.20–1.17, n¼ 25 of
103).
Conclusions: The IMPULSE study showed no relevant effect of lefitolimod on the main efficacy end point OS in the ITT, but (1)
the expected pharmacodynamic response to lefitolimod, (2) positive OS efficacy signals in two predefined subgroups and (3) a
favorable safety profile. These data support further exploration of lefitolimod in SCLC.
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Introduction
Most patients with small-cell lung cancer are diagnosed with
extensive-stage small-cell lung cancer (ES-SCLC). Platinum-
based combination chemotherapy provides response in at least
two-thirds of patients and improves median survival from 3 to
10 months, approximately. On progression, second-line therapy
yields response rates of 20%–30%, with median survival times of
6–8 months [1]. Based on the outcome of research over the last
decades, SCLC has been referred to as ‘a graveyard for drug devel-
opment’ and most patients succumb to the disease within 2 years
[2]. Thus, the development of treatment options to delay cancer
progression and to prolong survival after initial therapy is an un-
met need.
In the past it has been shown that VEGFR-inhibition with
sunitinib may have impact in this clinical setting [3]. In the rap-
idly moving field of immuno-oncology, phase III trials assess
immune checkpoint inhibition with consecutive maintenance
within first-line chemotherapy. These strategies are based on
the rationale that chemotherapy not only leads to initial rapid
tumor shrinkage with a limited period of disease stability, but
also to release of tumor-associated antigens (TAA) as ideal
immune targets. The subsequent application of checkpoint-
inhibiting antibodies blocks the pathways causing downregula-
tion of the immune response against TAA. ES-SCLC with its
high initial response rates to standard platinum-based chemo-
therapy, a resulting decrease of tumor burden and associated
release of TAA could be an ideal setting for such immunothera-
peutic strategies [4, 5]. Nevertheless, addition of ipilimumab
to chemotherapy did not prolong overall survival (OS)
versus chemotherapy alone in patients with newly diagnosed
ES-SCLC [6].
However, an efficacious adaptive immune response requires
processing and presentation of TAA by dendritic cells as well as
allocation of the appropriate cytokine and chemokine environ-
ment through cells of the innate immune system. All such im-
munological requirements for immune surveillance reactivation
are fulfilled by the mode-of-action of lefitolimod (MGN1703).
Therefore, it was considered as particularly promising for main-
tenance therapy in ES-SCLC.
Lefitolimod, a TLR9 agonist, comprises covalently closed
DNA molecules without chemical or other non-natural modifi-
cations, which is crucial for its favorable safety and tolerability
features [7, 8]. Lefitolimod targets TLR9-positive plasmacytoid
dendritic cells (pDCs) and triggers their secretion of IFN-alpha
to activate the effector cells of innate immunity (e.g. mono-
cytes) subsequently leading to high systemic levels of IFN-
gamma-induced protein 10 (IP-10/CXCL10) [9], a chemotactic
and angiostatic protein [10]. IFN-alpha results also in activation
of myeloid dendritic cells (mDC) for efficacious presentation of
TAA to CD4þ but more importantly for cross-presentation of
TAA to CD8þ T cells [11]. In previous phases I and II studies
lefitolimod showed a favorable safety profile, activation of anti-
tumor immunity and early signs of immunotherapeutic efficacy
[7, 12, 13].
Here we report on a randomized phase II trial assessing the effi-
cacy and safety of lefitolimod as a maintenance strategy in ES-
SCLC showing objective tumor response after platinum-based
combination chemotherapy.
Patients and methods
Detailed descriptions are available in supplementary methods, available
at Annals of Oncology online.
Patients
Patients with ES-SCLC and objective tumor response to four cycles of
platinum-based first-line therapy with a platinum-based chemothera-
peutic regimen were included.
Study design
IMPULSE (ClinicalTrials.gov: NCT02200081) is a randomized, inter-
national, multicenter, open-label exploratory phase II trial for OS signal
generation. ES-SCLC patients were randomized 3 : 2 to receive lefitoli-
mod maintenance therapy (twice-weekly, 60 mg s.c.) or local standard of
care until progression or unacceptable toxicity (Figure 1A).
Outcome measures
The main efficacy end point was OS in the intent-to-treat (ITT) popula-
tion. Secondary outcome measures included safety, objective response
rate (ORR), progression-free survival (PFS), preplanned subgroup analy-
ses and immunological assessments.
Results
Patient characteristics
From a total of 133 patients screened, 103 patients were enrolled
with 62 patients randomized to the lefitolimod and 41 to the con-
trol arm by 41 centers in Belgium, Austria, Germany and Spain
(Figure 1B). In general, there was a balanced distribution between
the two treatment arms regarding demographic factors such as
age, sex, race, smoking status, reported COPD and brain metasta-
sis (supplementary Table S1, available at Annals of Oncology on-
line). However, some imbalance in the ECOG performance status
in favor of the control arm was noted with 30.6% of patients in
the lefitolimod arm versus 46.3% of patients in the control group
exhibiting ECOG 0. On top of ECOG, there was an imbalance in
prophylactic irradiation during the treatment phase with 16.4%
in the treatment and 43.6% in the control arm, respectively (sup-
plementary Table S2, available at Annals of Oncology online).
Confirmation of lefitolimod’s mode-of-action
Lefitolimod broadly activates the immune system by targeting
predominately TLR9-positive pDC (Figure 2A). This mode-of-
action was confirmed in the lefitolimod-treated patients with a
clear activation of peripheral monocytes shown by an upregula-
tion of CD169 and elevated IP-10 serum levels in response to sub-
cutaneous lefitolimod treatment (Figure 2B and C), whereas only
minor changes occurred in the control patients.
Objective response rate and progression-free
survival
There was a trend toward a higher ORR in the lefitolimod arm
(11.9%) versus the control arm (8.1%) with an odds ratio of 1.57
(supplementary Table S3, available at Annals of Oncology online).
The PFS within the ITT showed no significant difference
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Figure 1. Design of IMPULSE study and CONSORT report chart. (A) Schematic ﬂow chart of IMPULSE, a randomized, controlled, two-arm,
multinational phase II clinical trial. (B) CONSORT chart of patient distribution.
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(Figure 3A). However, a group of lefitolimod patients exhibited a
slower progression with two of them reaching long-term disease
control beyond study end (720 days) (supplementary Figure S1,
available at Annals of Oncology online).
OS in the ITT population
Kaplan–Meier analysis revealed no relevant difference between
the study arms with a median OS of 279 days for the lefitolimod
and 274 days for the control group, respectively, and a hazard
ratio (HR) of 1.14 (95% CI: 0.73–1.76) comparing 62 lefitolimod
with 41 control patients (Figure 3B).
OS in two predefined subgroups
Chronic obstructive pulmonary disease (COPD) is a frequent
underlying disease in SCLC [14]. An OS signal was observed in
patients with reported COPD at baseline with a median OS of
316 versus 246 days in the lefitolimod and control group, respect-
ively, and an HR of 0.48 (95% CI: 0.20–1.17) (Figure 4A).
To gain more understanding in the immunological mode-of-
action we divided patients at baseline in two groups based on the
frequency of CD86þ B cells previously described as activated B
cells [15]. In fact, in the predefined subgroup of patients with a
low number of activated B cells using a cutoff of 15.4% an OS
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signal could be detected with a median OS of 300 versus 232 days
and an HR of 0.53 (95% CI: 0.26–1.08) (Figure 4B). The robust-
ness of this signal was confirmed using different cutoffs like me-
dian, quartiles and quintiles for which a consistent benefit of
patients with a low number of B cells was detected (Figure 4C).
Post hoc analysis
Patients benefitting from immunotherapy are typically found in a
minor subgroup. Here, we distributed the patients into sub-
groups of short-, medium- and long-lasting responders (PFS
80 days, 81–149 days and 150 days, respectively) with mainly
radiologic progression as events for PFS determination. A clear
association of prolonged PFS with an advantage in OS was
detected in lefitolimod patients (HR 0.23, 95% CI: 0.10–0.53 for
long-lasting versus short-lasting responders). This does not hold
true for control patients (supplementary Figure S2, available at
Annals of Oncology online).
Another post hoc analysis revealed that strong lefitolimod-
induced immune activation—represented as increase of IP-10 or
CD169þ monocytes—translated into an OS benefit with HR of
0.66 (95% CI: 0.38–1.15) or 0.50 (95% CI: 0.28–0.90), respective-
ly, when analyzed after 4 weeks of treatment (supplementary
Figures S3 and S4, available at Annals of Oncology online).
Safety profile
Lefitolimod showed a favorable safety profile in this vulnerable
population. The most common treatment-emergent adverse
events (AEs) are presented in supplementary Table S4, available
at Annals of Oncology online. One SUSAR of grade 2 leukoence-
phalopathy in a patient treated with platinum-based chemother-
apy was reported. Patients received twice-weekly subcutaneous
injections of lefitolimod for up to 2 years. High treatment adher-
ence was established with 2031 of 2143 (94.8%) planned doses
administered. Only four patients had temporary treatment
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interruptions due to AE not recurring under resumption of treat-
ment. No patient discontinued or had a dose reduction due to an
AE.
Discussion
For the last 30 years, there was no important therapeutic advance
in ES-SCLC leading this indication to be designated a recalcitrant
cancer [5]. While also the IMPULSE trial in ES-SCLC indicated
no improvement of OS in the ITT population, encouraging OS
signals were detected in two predefined patient subgroups: (i)
Patients with a reported history of COPD and (ii) patients with a
low number of activated B cells.
COPD is known as independent risk factor for SCLC [14].
A recent publication indicates an importance of circulating
immune-cell alterations in the pathophysiology of COPD [16].
Indeed, we observed an OS signal in lefitolimod patients with
reported COPD at baseline. Interestingly, the initial immune cell
infiltration in COPD creates a tumor-suppressive environment.
However, during persistent COPD chronic inflammation evolves
which may in turn facilitate tumor growth [17]. It may be specu-
lated that the imbalanced immune environment in COPD is fa-
vorably influenced by lefitolimod-induced immune activation.
Unfortunately, for this relatively small subgroup of patients with
reported COPD (25/103), no detailed information about the im-
mune status was available precluding further meaningful analysis
of immune markers.
For 88 patients, we were able to measure the frequency of acti-
vated CD86þ B cells at baseline. The cutoff separating patients
with low or high proportions of activated B cells placed 38
patients (43%) into the group with <15.4% of activated B cells.
Here, lefitolimod maintenance exerted a noteworthy effect on
OS. Activated B cells as characterized here include a population
of B cells with regulatory function (Breg). Differentiation of im-
mune cell precursors into Breg is initiated by cytokines secreted by
tumor cells and active Breg suppress antitumor responses through
inhibition of cytotoxic T cells, NK cells and M1-polarized macro-
phages [18–20]. Hence, the presence of a high number of Breg,
reflected by a high proportion of activated B cells, likely inhibits
the antitumor effects driven by lefitolimod (Figure 4D). Thus, a
low proportion of activated B cells may be developed as a predict-
ive biomarker for the identification of patients benefiting from
maintenance treatment with lefitolimod.
While no relevant PFS benefit for the treatment arm was
shown a group of lefitolimod patients exhibited slower pro-
gression with two patients reaching long-term disease control
(supplementary Figure S1, available at Annals of Oncology on-
line). In keeping with this, a trend toward a higher ORR in the
lefitolimod arm was observed. In a post hoc analysis, patients
with short-, medium- and long-lasting responses were ana-
lyzed for OS and a strong direct association between PFS and
OS benefit is evident in lefitolimod but not in control patients
(supplementary Figure S2, available at Annals of Oncology on-
line). While in ES-SCLC only weak to moderate associations
between PFS and OS were observed with standard treatments
[21, 22], strong direct PFS to OS associations are a common
feature of other immunotherapies. They herein identify a
group of patients benefitting from immunotherapy with lefito-
limod as well.
Corroborating the mode-of-action of lefitolimod, this study
showed a strong and significant increase of CD169þ monocytes
as well as of IP-10 within the lefitolimod-treated population.
Furthermore, lefitolimod-induced immune activation translated
into beneficial OS effects (supplementary Figure S3 and S4, avail-
able at Annals of Oncology online). Hence, these biomarkers may
have the potential for monitoring and guiding lefitolimod
treatment.
The favorable safety profile of lefitolimod, described in previ-
ous reports [12, 13], was largely confirmed in the current trial.
Headache, nausea, asthenia and fatigue are consistent with the
mode-of-action expressed by flu-like symptoms in a population
recovering from chemotherapy. It can be speculated that cough
may also be supported by the mode-of-action in lung cancer
patients.
Few drugs undergo evaluation or have recently been investi-
gated in maintenance treatment after first-line chemotherapy in
(ES-)SCLC. One is sunitinib, for which a significant PFS im-
provement did not translate to improved OS [3]. Earlier temsiro-
limus (CCI 779), given at 25 or 250 mg weekly in maintenance,
seemed not to increase PFS in ES-SCLC [23]. Topotecan follow-
ing cisplatin and etoposide improved PFS but failed to improve
OS in ES-SCLC [24].
Another drug currently evaluated in maintenance in an on-
going phase III trial is the antibody-drug-conjugate rovalpituzu-
mab tesirine (Rova-T), which targets Delta-like protein 3
(DLL3), a ligand of the Notch1 receptor [25]. In a phase I expan-
sion cohort of advanced treatment lines of ES-SCLC Rova-T
showed promising results with respect to response rate and dis-
ease control rate [26]. Therefore, the Rova-T is currently eval-
uated in a randomized phase III trial, with high DLL3 expression
as a predictive biomarker. However, preliminary results from a
phase II trial in third-line patients with relapsed or refractory
DLL3-expressing SCLC look less promising [27].
Since results from phase I or phase II trials seemed promising
[2, 4], treatment options with checkpoint inhibition are quickly
expanded into phase III trials, even combinations in conjunc-
tion with chemotherapy, allowing for extension into mainten-
ance treatment. A phase I trial of the anti-PD-1-antibody
pembrolizumab in ES-SCLC patients resulted in an ORR
of 33% [28]. Notably, an OS of 9.2 months reported
for pembrolizumab in maintenance after 4–6 cycles of chemo-
therapy was in a similar range as observed in the IMPULSE
study [29].
Due to the blinded IMPULSE study design, the early withdraw-
al of consent by four control patients could not be compensated
and—together with imbalances in ECOG and prophylactic ir-
radiation during treatment which seem to favor the control arm
in the population studied—limits the explanatory power of this
arm as result of the small sample size.
In summary, the IMPULSE study yielded evidence that treat-
ment with lefitolimod is feasible and safe in ES-SCLC and that es-
pecially low counts of activated B cells may be useful as a
predictive biomarker for a beneficial OS effect. Keeping in mind
that this indication is regarded as a ‘recalcitrant cancer’ [5] and a
‘graveyard for drug development’ [2], with the data presented
here there is a clear rationale for further exploration of lefitoli-
mod alone or in combination with other immune-oncological
approaches in ES-SCLC.
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